Budesonide for EoE: Biopsies and Swallowing Symptoms

Bring your pathology report and medicine packaging to an appointment about eosinophilic esophagitis, or EoE. Ask the gastroenterologist to explain how the planned review will assess both swallowing and the biopsy findings. Record which foods cause difficulty and any changes you have made to finish a meal.

What the trial measured

Researchers randomized 77 adults; 76 were analyzed, including 13 women, across four groups for 14 days. Treatments were budesonide tablets 1 mg twice daily, tablets 2 mg twice daily, suspension 2 mg twice daily, or placebo.¹

Primary histologic remission meant mean density below 16 eosinophils/mm² across 30 biopsy fields, not a symptom-free patient. Rates were 19/19, 18/19, 18/19 and 0/19, respectively (all P<.0001 versus placebo). A planned interim analysis stopped recruitment for efficacy. The small study did not establish formulation or dose equivalence.¹

What swallowing scores showed

At treatment end, swallowing scores improved in every group, without significant between-group differences. These exploratory assessments used a nonvalidated scale. This short trial cannot establish lasting symptom control. Fungal staining was positive in two people per active arm. Sponsor Dr. Falk Pharma employed three authors; several others reported financial ties.¹

Which prescription you are discussing

The current UK Jorveza tablet label covers adult EoE. It lists a usual six-week induction course, extendable to twelve weeks for inadequate response. Its instructions say to let the tablet disintegrate in the mouth and swallow the saliva gradually; do not chew it or swallow it undissolved. Ask the pharmacist to demonstrate the prescribed product’s instructions.²

Do not use the short study to substitute a tablet for a liquid prescription. Have the prescriber identify the exact preparation, local indication and planned duration. A matching ingredient name does not establish an interchangeable regimen.

Jorveza’s label warns about Candida infection and systemic steroid effects, including adrenal suppression. Liver impairment affects suitability. Clarithromycin, ritonavir and grapefruit juice can increase budesonide exposure. Bring all prescriptions, supplements and other steroid products for an interaction and cumulative-exposure review. Discuss pregnancy or breastfeeding before treatment.²

How treatment will be reviewed

ACG’s patient guidance says endoscopy with biopsies is needed after starting or changing treatment. Ask when that assessment will happen and how its findings will affect the plan. A swallowing diary helps describe your meals, but it cannot replace the scheduled biopsy review.³

If narrowing requires dilation, ACG explains that dilation does not treat the inflammation; anti-inflammatory treatment is still needed. Ask which part of your plan addresses narrowing and which addresses inflammation.³

Food stuck in the esophagus that will not move up or down needs emergency care. Persistent difficulty swallowing warrants medical assessment. Do not wait for a routine treatment-review appointment with an obstruction.³

Bloated by Dinner includes swallowing difficulty in its “Test It” warning signs. “The Visit Script” helps organize your symptom pattern, medicines and next-step questions before a digestive-health appointment.